Cannabinoids for Tourette's Syndrome (Q24240148)

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

The therapeutic potential of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Effective treatment of Tourette's syndrome with marijuana.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Psychiatric effects of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Localization of cannabinoid receptor mRNA in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Molecular characterization of a peripheral receptor for cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

A community survey of adverse effects of cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Treatment of ADHD in children with tics: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006565.PUB2

Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.

21 January 2018

1 reference

12 December 2020

The validity of instruments measuring tic severity in Tourette's syndrome

1 reference

12 December 2020

Treatment of Tourette's syndrome with transdermal clonidine: a pilot study

1 reference

12 December 2020

Controlled Study of Pimozide vs. Placebo in Tourette's Syndrome

1 reference

12 December 2020

Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.

1 reference

12 December 2020

Marijuana and Tourette's syndrome

1 reference

12 December 2020

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

12 December 2020

Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods

1 reference

12 December 2020